| scholarly article | Q13442814 |
| P50 | author | John P Ney | Q57059524 |
| P2093 | author name string | Kevin R Joseph | |
| P2860 | cites work | Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response | Q47951905 |
| New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm | Q47967002 | ||
| The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection | Q47997311 | ||
| Meige syndrome: primary and secondary forms | Q48160794 | ||
| BoNT/E prevents seizure-induced activation of caspase 3 in the rat hippocampus | Q48199025 | ||
| Reduction of EEG myogenic artifact with botulinum toxin during video-EEG monitoring | Q48275216 | ||
| Microvascular decompression for hemifacial spasm: a long-term follow-up of 1,169 consecutive cases | Q48448331 | ||
| Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A. | Q48465683 | ||
| The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture | Q48546476 | ||
| Needle-free anaesthesia prior to botulinum toxin type A injection treatment of palmar and plantar hyperhidrosis | Q48621750 | ||
| Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements | Q48850713 | ||
| Botulinum toxin type A therapy for hemifacial spasm | Q24244891 | ||
| Botulinum toxin type A therapy for cervical dystonia | Q24244957 | ||
| Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy | Q24245806 | ||
| Botulinum toxin type A therapy for blepharospasm | Q24247236 | ||
| Pain mechanisms: labeled lines versus convergence in central processing | Q28185812 | ||
| Clostridium botulinum toxins | Q28609198 | ||
| Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction | Q30766977 | ||
| Update on botulinum toxin | Q33261059 | ||
| Treatment of bruxism with botulinum toxin injections | Q33588992 | ||
| Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy | Q33909825 | ||
| Hyperhidrosis: evolving therapies for a well-established phenomenon | Q33987042 | ||
| Pain mechanisms and management: a central perspective | Q34051148 | ||
| Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs | Q34086661 | ||
| Hemifacial spasm and involuntary facial movements | Q34141613 | ||
| Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review | Q34147258 | ||
| Treatment of temporomandibular disorders with botulinum toxin | Q34175389 | ||
| Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as "Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift für Hygiene und Infektionskra | Q34198222 | ||
| Pharmacologic weakening of extraocular muscles. | Q34204174 | ||
| The peripheral apparatus of muscle pain: evidence from animal and human studies. | Q34209469 | ||
| Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. | Q34253641 | ||
| SNARE complex structure and function | Q34430515 | ||
| Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? | Q34448873 | ||
| Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects | Q34481657 | ||
| Therapeutic use of botulinum toxins: background and history | Q35060549 | ||
| Possible mechanisms for the effects of botulinum toxin on pain | Q35060554 | ||
| Considering the immune response to botulinum toxin | Q35060558 | ||
| A focused review of the use of botulinum toxins for low back pain | Q35060564 | ||
| Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. | Q35068975 | ||
| Focused review: Botulinum toxin type A therapy in chronic pain disorders | Q35112160 | ||
| Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study | Q35457278 | ||
| Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin | Q35478697 | ||
| Treatment of cervical dystonia with botulinum toxin | Q35693995 | ||
| Botulinum toxin treatment of occupational and focal hand dystonia | Q35693998 | ||
| Botulinum toxin treatment of secretory disorders | Q35694006 | ||
| Botulinum toxins in neurological disease | Q35759634 | ||
| Treatment of hemifacial spasm with botulinum toxin | Q35797269 | ||
| Botulinum toxin in clinical practice | Q35807826 | ||
| Dysport | Q35820176 | ||
| Safety of botulinum toxin type A: a systematic review and meta-analysis | Q35841671 | ||
| Expanding use of botulinum toxin. | Q36180106 | ||
| Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. | Q36185790 | ||
| Controlling sialorrhoea: a review of available treatment options | Q36221996 | ||
| A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia | Q36317676 | ||
| Pharmacotherapy of spasticity in children with cerebral palsy | Q36352643 | ||
| Unlabeled uses of botulinum toxins: a review, part 1. | Q36359589 | ||
| Pharmacology of botulinum toxin: differences between type A preparations | Q36370612 | ||
| Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc | Q36370617 | ||
| Treatment of cervical dystonia with botulinum toxins | Q36370621 | ||
| Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations | Q36370626 | ||
| Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations | Q36370631 | ||
| Management of spasticity in adults: practical application of botulinum toxin | Q36370640 | ||
| Botulinum toxin therapy of writer's cramp | Q36370650 | ||
| Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations | Q36370654 | ||
| Status on the use of botulinum toxin for headache disorders | Q36479969 | ||
| Answers to frequently asked questions about migraine | Q36621666 | ||
| Why the most potent toxin may heal anal fissure | Q36627933 | ||
| The structure and mode of action of different botulinum toxins | Q36656462 | ||
| Clinical value of botulinum toxin in neurological indications | Q36656469 | ||
| Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. | Q52887503 | ||
| Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. | Q52902731 | ||
| Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. | Q53125749 | ||
| Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. | Q53663140 | ||
| A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. | Q53890864 | ||
| Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. | Q54035267 | ||
| Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. | Q54194917 | ||
| The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. | Q54334283 | ||
| Dystonia. | Q55042366 | ||
| A pilot study on the use of botulinum toxin in spasmodic torticollis. | Q55061325 | ||
| Botulinum toxin treatment of spasmodic torticollis. | Q55554726 | ||
| Hemifacial spasm | Q56864937 | ||
| Botulinum Toxin in the Treatment of Refractory Vaginismus | Q56882642 | ||
| Botulinum Toxin in Headache Treatment: The End of the Road? | Q57024415 | ||
| Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain | Q57245544 | ||
| Treatment of Chronic Low Back Pain With Successive Injections of Botulinum Toxin A Over 6 Months | Q57458079 | ||
| Treatment of Low Back Pain with Botulinum Neurotoxins | Q57458096 | ||
| Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 | Q57979097 | ||
| DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1 | Q58870363 | ||
| A randomized trial of botulinum toxin A for treatment of drooling | Q60360007 | ||
| Functional Outcomes of Intramuscular Botulinum Toxin Type A and Occupational Therapy in the Upper Limbs of Children With Cerebral Palsy: A Randomized Controlled Trial | Q60484880 | ||
| Upper-Limb Botulinum Toxin A Injection and Occupational Therapy in Children With Hemiplegic Cerebral Palsy Identified From a Population Register: A Single-Blind, Randomized, Controlled Trial | Q60620069 | ||
| Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a Stroke | Q61697961 | ||
| Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study | Q63436954 | ||
| Adult-onset primary lower limb dystonia | Q63952485 | ||
| Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction | Q66829168 | ||
| Benign essential blepharospasm | Q66829477 | ||
| In vitro microelectrode study of neuromuscular transmission in a case of botulism | Q67487244 | ||
| Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance | Q68097157 | ||
| Botulinum toxin injection for the treatment of oromandibular dystonia | Q69946815 | ||
| Botulinum toxin injection therapy in the management of lower urinary tract dysfunction. | Q36683984 | ||
| Botulinum toxin A in the treatment of sialorrhea | Q36693215 | ||
| Botulinum toxin in ophthalmology | Q36703189 | ||
| Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia | Q36770303 | ||
| The Janus faces of botulinum neurotoxin: sensational medicine and deadly biological weapon | Q36771531 | ||
| The status of botulism as a world health problem | Q36881039 | ||
| Blepharospasm and its treatment, with emphasis on the use of botulinum toxin | Q38604320 | ||
| Botulinum toxin type-A in therapy of patients with anismus | Q39222614 | ||
| Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience | Q39342325 | ||
| The guidelines for the diagnosis and treatment of spasticity. | Q39343513 | ||
| Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study | Q39351109 | ||
| Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study | Q39362454 | ||
| Botulinum toxin A and chronic low back pain: a randomized, double-blind study | Q39418398 | ||
| Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin | Q39473584 | ||
| Botulinum A toxin effects on rat jaw muscle spindles | Q39494040 | ||
| Treatment of blepharospasm with botulinum toxin | Q39522823 | ||
| Double-blind study of botulinum toxin in spasmodic torticollis | Q39542317 | ||
| A hypothesis on the physiological basis for causalgia and related pains | Q39730686 | ||
| SV2 is the protein receptor for botulinum neurotoxin A. | Q40303506 | ||
| The mechanism of action of tetanus and botulinum neurotoxins | Q41014589 | ||
| Botulism in the United States: a clinical and epidemiologic review | Q42053667 | ||
| Historical note on the therapeutic use of botulinum toxin in neurological disorders | Q42073553 | ||
| Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs | Q42652856 | ||
| New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia | Q42765955 | ||
| Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation | Q43009767 | ||
| Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin | Q44320261 | ||
| Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia | Q44394591 | ||
| Botulinum toxin (botox) reduces pain after hemorrhoidectomy: results of a double-blind, randomized study | Q44542528 | ||
| Subcutaneous administration of botulinum toxin A reduces formalin-induced pain | Q44722571 | ||
| Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. | Q44759026 | ||
| Sialorrhea: a management challenge | Q44940638 | ||
| Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. | Q45041174 | ||
| Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. | Q45961097 | ||
| Systemic toxicity of botulinum toxin by intramuscular injection in the monkey | Q46083035 | ||
| Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety | Q46220421 | ||
| Gustatory sweating: Frey syndrome | Q46848024 | ||
| Topical botulinum toxin to treat hyperhidrosis? No sweat! | Q46981020 | ||
| Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke | Q47228741 | ||
| Clostridium botulinum: an increasing complication of heroin misuse | Q47724665 | ||
| Botulinum A toxin injection as a treatment for blepharospasm | Q70069053 | ||
| Botulinum toxin in the treatment of writer's cramp: a double-blind study | Q70537913 | ||
| An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse | Q70599485 | ||
| Cervical dystonia and botulinum treatment: is electromyographic guidance necessary? | Q71374808 | ||
| Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial | Q72001209 | ||
| Response and immunoresistance to botulinum toxin injections | Q72059963 | ||
| Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections | Q72319736 | ||
| Botulinum toxin A in the hemiplegic upper limb: a double-blind trial | Q73252837 | ||
| Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up | Q73276590 | ||
| Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A | Q73351261 | ||
| Botulinum toxin: the story of its development for the treatment of human disease | Q73375172 | ||
| Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism | Q73472804 | ||
| Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group | Q73883800 | ||
| Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-contr | Q74107584 | ||
| An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy | Q74254526 | ||
| Contribution of group III and IV muscle afferents to multisensorial spinal motor control in cats | Q77352242 | ||
| Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy | Q77422149 | ||
| Comparison of Botox with a Chinese type A botulinum toxin | Q77446738 | ||
| Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial | Q77492793 | ||
| Common patterns of clinical motor dysfunction | Q77594615 | ||
| Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group | Q77594655 | ||
| Accuracy of muscle localization without EMG: implications for treatment of limb dystonia | Q77754473 | ||
| Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm | Q77944561 | ||
| Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period | Q78609665 | ||
| Botulinum toxin type A influences stump pain after limb amputations | Q79342240 | ||
| Drooling | Q79350891 | ||
| Botulinum neurotoxins: origins and basic mechanisms of action | Q79385326 | ||
| A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis | Q79619688 | ||
| A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm | Q79711707 | ||
| Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins | Q80112658 | ||
| Botulinum toxin in headache treatment: the end of the road? | Q80191700 | ||
| [Botulinum toxin for treatment of gustatory sweating. A prospective randomized study] | Q80938765 | ||
| Adult-onset primary focal foot dystonia | Q81195795 | ||
| Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia | Q81637626 | ||
| Botulinum toxin: mechanisms of action | Q81649501 | ||
| A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot | Q81721537 | ||
| Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial | Q95820918 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 785-798 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Neuropsychiatric Disease and Treatment | Q15716332 |
| P1476 | title | Neurologic uses of botulinum neurotoxin type A | |
| P478 | volume | 3 |
| Q36115292 | A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases. |
| Q33696587 | AbobotulinumtoxinA: A 25-Year History |
| Q55456919 | Bacterial Toxins and Targeted Brain Therapy: New Insights from Cytotoxic Necrotizing Factor 1 (CNF1). |
| Q38874264 | Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life |
| Q42207124 | Botulinum toxin - From WMD to therapeutic agent and cosmetic aid. |
| Q37888668 | Botulinum toxin A (Dysport®): in dystonias and focal spasticity. |
| Q94322481 | Botulinum toxin for drooling in Parkinson’s disease |
| Q84654072 | Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations |
| Q39215110 | Effect of Clostridium botulinum toxin type A injections into the deep digital flexor muscle on the range of motion of the metacarpus and carpus, and the force distribution underneath the hooves, of sound horses at the walk |
| Q35548169 | Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons |
| Q33696581 | Introduction to the Supplement: A Review of AbobotulinumtoxinA (Dysport). |
| Q35647787 | Neuronox versus BOTOX in the Treatment of Post-Stroke Upper Limb Spasticity: A Multicenter Randomized Controlled Trial |
| Q33696618 | New Uses of AbobotulinumtoxinA in Aesthetics |
| Q41456154 | Spasticity mechanisms - for the clinician |
| Q40159672 | The effect of Clostridium botulinum toxin type A injections on motor unit activity of the deep digital flexor muscle in healthy sound Royal Dutch sport horses |
| Q38917548 | Treatment Effects for Dysphagia in Adults with Multiple Sclerosis: A Systematic Review |
| Q92534387 | Ultrasound Elastography to Assess Botulinum Toxin A Treatment for Post-stroke Spasticity: A Feasibility Study |
Search more.